Scholarlink

Purpose <p>To evaluate the budget impact on the China’s basic medical insurance fund (BMIF) following the inclusion of aztreonam-avibactam (ATM-AVI) for metallo-β-lactamase carbapenem-resistant enterobacterales (MBL-CRE) infections in the National Reimbursement Drug List (NRDL).</p> Methods <p>A budget impact model was developed with a 2-year time horizon (2026–2027) from the perspective of China’s basic medical insurance. The analysis included drug acquisition costs and other direct medical costs. Relevant data were collected from published literature, and supplemented through expert consultation. The study compared costs under two scenarios with and without ATM-AVI reimbursement to estimate its impact on BMIF. One way sensitivity analyses were conducted to identify key parameters influencing the results.</p> Results <p>After the inclusion of ATM-AVI in the NRDL, the BMIF was projected to save 152,156,598 Chinese yuan (21,310,448 United States dollar) and 210,914,875 Chinese yuan (29,539,898 United States dollar) in 2026 and 2027, respectively. Following reimbursement, ATM-AVI was expected to yield 291 and 342 additional cured patients, 804 and 888 fewer deaths, 11,256 and 13,031 fewer intensive care unit days, and 11,336 and 13,071 fewer total hospitalization days in 2026 and 2027, respectively. Across all parameter variations, ATM-AVI remained cost-saving to BMIF.</p> Conclusion <p>In China, timely reimbursement of innovative antibiotics can simultaneously improve patient outcomes and reduce medical insurance fund expenditure, underscoring the value of value-based reimbursement policies in promoting access to effective therapies while supporting the sustainability of the health insurance system.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China

  • 期刊论文

  • 发表日期：

    2026年5月4日

查看全文
  • Junling Weng,
  • Kemiao Zhang,
  • Qiang Liu,
  • Dunming Xiao,
  • Zichun Zhou,
  • Yi Yang,
  • Xin Li,
  • Yingyao Chen

摘要

Purpose

To evaluate the budget impact on the China’s basic medical insurance fund (BMIF) following the inclusion of aztreonam-avibactam (ATM-AVI) for metallo-β-lactamase carbapenem-resistant enterobacterales (MBL-CRE) infections in the National Reimbursement Drug List (NRDL).

Methods

A budget impact model was developed with a 2-year time horizon (2026–2027) from the perspective of China’s basic medical insurance. The analysis included drug acquisition costs and other direct medical costs. Relevant data were collected from published literature, and supplemented through expert consultation. The study compared costs under two scenarios with and without ATM-AVI reimbursement to estimate its impact on BMIF. One way sensitivity analyses were conducted to identify key parameters influencing the results.

Results

After the inclusion of ATM-AVI in the NRDL, the BMIF was projected to save 152,156,598 Chinese yuan (21,310,448 United States dollar) and 210,914,875 Chinese yuan (29,539,898 United States dollar) in 2026 and 2027, respectively. Following reimbursement, ATM-AVI was expected to yield 291 and 342 additional cured patients, 804 and 888 fewer deaths, 11,256 and 13,031 fewer intensive care unit days, and 11,336 and 13,071 fewer total hospitalization days in 2026 and 2027, respectively. Across all parameter variations, ATM-AVI remained cost-saving to BMIF.

Conclusion

In China, timely reimbursement of innovative antibiotics can simultaneously improve patient outcomes and reduce medical insurance fund expenditure, underscoring the value of value-based reimbursement policies in promoting access to effective therapies while supporting the sustainability of the health insurance system.